Low-dose antithyroid drug therapy for Graves' disease relapse is as effective as radioiodine (RAI) treatment in preventing further relapse, with Graves' ophthalmopathy showing even greater improvement with the drug therapy, according to a new study published in the journal Thyroid.
"Our findings demonstrated that for patients who relapse from the conventional use of antithyroid drugs after 12 to 18 months and do not desire a definitive treatment with RAI or surgery, the use of a prolonged low methimazole [MMI] dose is a feasible option," lead author Danilo Villagelin, MD, of the School of Medicine at Pontifical University Catholic of Campinas, Campinas, Brazil, told Medscape Medical News.
While antithyroid drug therapy is well-established as a treatment option for hyperthyroidism due to Graves' disease, research shows remission rates can range from 30% to as high as 70%, prompting some doctors to recommend RAI treatment or thyroid surgery as more definitive resolutions.
The latter approaches have their own undesirable effects, however, including the need for lifetime thyroid-hormone replacement and increased risk of hypothyroidism.
cont/d...